tradingkey.logo

tradingkey.logo
怜玢


Bolt Biotherapeutics Inc

BOLT
りォッチリストに远加
6.080USD
+0.170+2.88%
終倀 11-13 16:00ET
15.75M時䟡総額
損倱額盎近12ヶ月PER

Bolt Biotherapeutics Incに぀いお 䌁業名

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Bolt Biotherapeutics Inc プロフィヌル


䌁業コヌドBOLT
䌚瀟名Bolt Biotherapeutics Inc
䞊堎日Feb 05, 2021
最高経営責任者「CEO」Quinn (William P)
埓業員数52
蚌刞皮類Ordinary Share
決算期末Feb 05
本瀟所圚地900 Chesapeake Drive
郜垂REDWOOD CITY
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号94063
電話番号16506659295
りェブサむトhttps://boltbio.com/
䌁業コヌドBOLT
䞊堎日Feb 05, 2021
最高経営責任者「CEO」Quinn (William P)

Bolt Biotherapeutics Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Chief Strategy Officer, Director
Chief Strategy Officer, Director
72.77K
--
Mr. William P. (Willie) Quinn
Mr. William P. (Willie) Quinn
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
2.95K
+21.59%
Mr. Grant Yonehiro
Mr. Grant Yonehiro
Chief Operating Officer
Chief Operating Officer
445.00
-6741.80%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Mr. Brian O'Callaghan
Mr. Brian O'Callaghan
Independent Director
Independent Director
--
--
Dr. Nicole Onetto, M.D.
Dr. Nicole Onetto, M.D.
Independent Director
Independent Director
--
--
Dr. Laura Berner
Dr. Laura Berner
Independent Director
Independent Director
--
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Chief Strategy Officer, Director
Chief Strategy Officer, Director
72.77K
--
Mr. William P. (Willie) Quinn
Mr. William P. (Willie) Quinn
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
2.95K
+21.59%
Mr. Grant Yonehiro
Mr. Grant Yonehiro
Chief Operating Officer
Chief Operating Officer
445.00
-6741.80%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Mr. Brian O'Callaghan
Mr. Brian O'Callaghan
Independent Director
Independent Director
--
--
Dr. Nicole Onetto, M.D.
Dr. Nicole Onetto, M.D.
Independent Director
Independent Director
--
--

よくある質問

Bolt Biotherapeutics Incの䞊䜍5名の株䞻は誰ですか


Bolt Biotherapeutics Incの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Sheila Gujrathi, M.D.

Bolt Biotherapeutics IncBOLTの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Bolt Biotherapeutics Incの株匏を保有しおいる機関は63瀟あり、保有株匏の総垂堎䟡倀は玄516.47Kで、党䜓の26.88%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-504316.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。